Pasithea Therapeutics (KTTA) Competitors

Pasithea Therapeutics logo
$0.47 -0.01 (-1.46%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$0.48 +0.00 (+0.21%)
As of 11/20/2026 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KTTA vs. KVAC, CRBP, ACRV, IMDX, and OKYO

Should you buy Pasithea Therapeutics stock or one of its competitors? Pasithea Therapeutics's main competitors and comparable companies include Keen Vision Acquisition (KVAC), Corbus Pharmaceuticals (CRBP), Acrivon Therapeutics (ACRV), Oncocyte (IMDX), and OKYO Pharma (OKYO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pasithea Therapeutics compare to Keen Vision Acquisition?

Keen Vision Acquisition (NASDAQ:KVAC) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Keen Vision Acquisition has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 532.91%. Given Pasithea Therapeutics' higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Keen Vision Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

51.7% of Keen Vision Acquisition shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 80.2% of Keen Vision Acquisition shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.71 beat Keen Vision Acquisition's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Keen Vision Acquisition Neutral
Pasithea Therapeutics Positive

Keen Vision Acquisition's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Keen Vision AcquisitionN/A N/A N/A
Pasithea Therapeutics N/A -48.79%-46.24%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keen Vision AcquisitionN/AN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A

Summary

Keen Vision Acquisition and Pasithea Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A

Corbus Pharmaceuticals has a beta of 2.8, suggesting that its stock price is 180% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Corbus Pharmaceuticals currently has a consensus target price of $35.67, suggesting a potential upside of 1,631.39%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 532.91%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Pasithea Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Corbus Pharmaceuticals had 6 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.71 beat Corbus Pharmaceuticals' score of -0.01 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Corbus Pharmaceuticals Neutral
Pasithea Therapeutics Positive

Pasithea Therapeutics' return on equity of -48.79% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus PharmaceuticalsN/A -100.96% -82.70%
Pasithea Therapeutics N/A -48.79%-46.24%

Summary

Corbus Pharmaceuticals beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acrivon TherapeuticsN/AN/A-$77.90M-$1.83N/A
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A

In the previous week, Acrivon Therapeutics had 13 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 13 mentions for Acrivon Therapeutics and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.71 beat Acrivon Therapeutics' score of 0.06 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Acrivon Therapeutics Neutral
Pasithea Therapeutics Positive

Pasithea Therapeutics' return on equity of -48.79% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Acrivon TherapeuticsN/A -75.22% -65.85%
Pasithea Therapeutics N/A -48.79%-46.24%

Acrivon Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 1,073.91%. Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 532.91%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Pasithea Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Acrivon Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Summary

Acrivon Therapeutics beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Insight Molecular Diagnostics?

Pasithea Therapeutics (NASDAQ:KTTA) and Insight Molecular Diagnostics (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Insight Molecular Diagnostics shares are held by institutional investors. 1.5% of Pasithea Therapeutics shares are held by insiders. Comparatively, 2.2% of Insight Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pasithea Therapeutics has higher earnings, but lower revenue than Insight Molecular Diagnostics. Insight Molecular Diagnostics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A
Insight Molecular Diagnostics$4.05M15.75-$50.22M-$1.25N/A

Pasithea Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 532.91%. Insight Molecular Diagnostics has a consensus target price of $5.75, suggesting a potential upside of 194.87%. Given Pasithea Therapeutics' higher possible upside, research analysts plainly believe Pasithea Therapeutics is more favorable than Insight Molecular Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Insight Molecular Diagnostics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Insight Molecular Diagnostics had 19 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 19 mentions for Insight Molecular Diagnostics and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.71 beat Insight Molecular Diagnostics' score of 0.58 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Positive
Insight Molecular Diagnostics Positive

Pasithea Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Insight Molecular Diagnostics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Pasithea Therapeutics has a net margin of 0.00% compared to Insight Molecular Diagnostics' net margin of -2,137.33%. Insight Molecular Diagnostics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A -48.79% -46.24%
Insight Molecular Diagnostics -2,137.33%N/A -105.13%

Summary

Insight Molecular Diagnostics beats Pasithea Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to OKYO Pharma?

Pasithea Therapeutics (NASDAQ:KTTA) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Pasithea Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

OKYO Pharma's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A -48.79% -46.24%
OKYO Pharma N/A N/A N/A

Pasithea Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 532.91%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 429.60%. Given Pasithea Therapeutics' higher probable upside, research analysts plainly believe Pasithea Therapeutics is more favorable than OKYO Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pasithea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OKYO Pharma
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/A-$20.43M-$1.37N/A
OKYO PharmaN/AN/A-$8.95MN/AN/A

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.5% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.71 beat OKYO Pharma's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Positive
OKYO Pharma Neutral

Summary

OKYO Pharma beats Pasithea Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTA vs. The Competition

MetricPasithea TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17.59M$3.93B$7.43B$10.86B
Dividend YieldN/A3.79%2.51%4.74%
P/E RatioN/A24.5831.2925.82
Price / SalesN/A15.328.115.44
Price / CashN/A21.9220.2520.77
Price / Book0.404.124.343.51
Net Income-$20.43M-$24.08M$3.51B$394.12M
1 Month Performance-2.83%-13.58%-10.59%-12.04%
1 Year Performance62.16%-7.97%-4.80%-11.42%

Pasithea Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTA
Pasithea Therapeutics
1.9091 of 5 stars
$0.47
-1.5%
$3.00
+532.9%
+14.2%$17.59MN/AN/A5
KVAC
Keen Vision Acquisition
N/A$11.51
flat
N/AN/A$63.37MN/AN/AN/A
CRBP
Corbus Pharmaceuticals
3.4976 of 5 stars
$2.74
-9.0%
$35.67
+1,201.7%
-82.4%$62.03MN/AN/A36
ACRV
Acrivon Therapeutics
3.0633 of 5 stars
$1.56
+9.1%
$13.50
+765.4%
-49.1%$61.36MN/AN/A76
IMDX
Oncocyte
4.4155 of 5 stars
$1.59
-10.7%
$8.33
+424.1%
N/A$58.25M$1.67MN/A58

Related Companies and Tools


This page (NASDAQ:KTTA) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners